With the Digital Care Act (DVG), structures were created to establish regular reimbursement for digital health applications (DiGA) in Germany. Evidence
for the positive care effect (pVE) of the DiGA is your ticket to the SHI market and thus to secure reimbursement. With the question which requirements of the authorities have to be
fulfilled, you will also come across the topic of evaluation of your app. We have summarized the most important facts for you.
information on evaluation of DiGA in the German market (in German)
Since 2016 and until 2019, the innovation fund has been promoting new forms of care within the German statutory health insurance system. New forms of managed care as well as the generation of
real world evidence is funded with an annual volume of 300 million euros. 225 million euros are provided for the promotion of new forms of managed
care and 75 million euros for real world evidence. The innovation committee set up at the
Federal Joint Committee (G-BA) defines the priorities and criteria for funding in so-called funding notices, carries out for expression-of-interest procedures and decides on the applications for
funding. The legal basis for the work of this innovation committee, are §§ 92a and 92b, Fifth Book of the Social Code (SGB V).
Read the full article here (in
German) or contact us for the article in English and for more information on the innovation funds and what you need to do to apply.
Regresses - Rather a perceived threat to the physician, but still a
serious obstacle for pharmaceutical companies
Whether justified or not, the fear of regresses of physicians is immense.
Whether the probability of regresses is low, the extent of damage can be great from a physician’s point of view. Many physicians are already afraid of the conspicuity itself.
Read the full article here (in German) or contact
us for the article in English and more information how to support your clients when facing regress.